Overview of the relocation
New address
24th to 26th floors of
Relocation period
After summer 2025
An affiliated company that will also be relocating at the same time
Background and purpose of the relocation
We believe that the concept of
New office features
The Office as the 'FACE' of the Global Headquarters
We define the role of our new headquarters as a space where proud and ambitious employees come together to create new value and support the ever-evolving
An Office Environment That Fosters Innovation
With an eye toward strengthening collaboration with government, academia, startups, and ventures, we will establish a new base for open innovation that promotes co-creation and cooperation with various business partners. Furthermore, while respecting diverse working styles within the company, we aim to create an environment where enhanced communication and collaboration among employees lead to further improvements in the quality and speed of business activities, fostering the creation of new value.
Further Enhancement of Safety and Security
As a healthcare provider,
Establishing a More Advanced Security Environment
As the core function of a pharmaceutical company handling information assets, we will construct a higher security environment. Recognizing information leakage as a critical risk for the company, we aim to create an environment where strict management of information maintains our competitive edge.
Utilizing the current head office
The current head office will continue to be utilized as an important base for
Although relocating our headquarters from the place where we were founded is a major decision, we believe that this is a necessary step for
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Contact:
Web: https://www.shionogi.com
(C) 2024 Electronic News Publishing, source